NCT04352777View on ClinicalTrials.gov

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

June 25, 2025

Study Completion Date

June 25, 2025

Conditions
Metastatic Breast CancerLocally Advanced Breast CancerHormone Receptor Positive Tumor
Interventions
DRUG

Abemaciclib

50 - 150mg tablet BID as prescribed per standard of care

DRUG

Fulvestrant

500mg as prescribed per standard of care

DRUG

Aromatase Inhibitors

Letrozole, anastrozole as prescribed per standard of care

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER